Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients
SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barré syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent researc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
2021-10-01
|
| Series: | Clinics |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100428&tlng=en |
| _version_ | 1818245223337164800 |
|---|---|
| author | Josef Finsterer Fulvio A. Scorza Carla A. Scorza |
| author_facet | Josef Finsterer Fulvio A. Scorza Carla A. Scorza |
| author_sort | Josef Finsterer |
| collection | DOAJ |
| description | SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barré syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent research reports. Altogether, nine articles reporting 18 patients with SCoVaG were identified and one more report on another patient is under review. The age for the studies ranged between 20-86y. Nine patients were male, and ten were female. In all 19 patients, SCoVaG developed after the first dose of the vaccine. The Astra Zeneca vaccine was used in fourteen patients, the Pfizer vaccine in four patients, and the Johnson & Johnson vaccine was applied in one patient. The latency between vaccination and onset of GBS ranged from 3h to 39d. The treatment of SCoVaG included IVIGs (n=13), steroids (n=3), or no therapy (n=3). Six patients required mechanical ventilation. Only a single patient recovered completely and partial recovery was achieved in nine patients. In conclusion, GBS may develop time-linked to the first dose of a SARS-CoV-2 vaccination. Though a causal relationship between SARS-CoV-2 vaccinations and SCoVaG remains speculative, more evidence is in favour than against it. |
| first_indexed | 2024-12-12T14:29:30Z |
| format | Article |
| id | doaj.art-ae7830a8d78d4c689289e8c629951159 |
| institution | Directory Open Access Journal |
| issn | 1980-5322 |
| language | English |
| last_indexed | 2024-12-12T14:29:30Z |
| publishDate | 2021-10-01 |
| publisher | Elsevier España |
| record_format | Article |
| series | Clinics |
| spelling | doaj.art-ae7830a8d78d4c689289e8c6299511592022-12-22T00:21:36ZengElsevier EspañaClinics1980-53222021-10-017610.6061/clinics/2021/e3286Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patientsJosef Finstererhttps://orcid.org/0000-0003-2839-7305Fulvio A. Scorzahttps://orcid.org/0000-0002-0694-8674Carla A. Scorzahttps://orcid.org/0000-0001-7810-4748SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barré syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent research reports. Altogether, nine articles reporting 18 patients with SCoVaG were identified and one more report on another patient is under review. The age for the studies ranged between 20-86y. Nine patients were male, and ten were female. In all 19 patients, SCoVaG developed after the first dose of the vaccine. The Astra Zeneca vaccine was used in fourteen patients, the Pfizer vaccine in four patients, and the Johnson & Johnson vaccine was applied in one patient. The latency between vaccination and onset of GBS ranged from 3h to 39d. The treatment of SCoVaG included IVIGs (n=13), steroids (n=3), or no therapy (n=3). Six patients required mechanical ventilation. Only a single patient recovered completely and partial recovery was achieved in nine patients. In conclusion, GBS may develop time-linked to the first dose of a SARS-CoV-2 vaccination. Though a causal relationship between SARS-CoV-2 vaccinations and SCoVaG remains speculative, more evidence is in favour than against it.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100428&tlng=enSARS-CoV-2COVID-19Neuro-COVIDComplicationsVaccinationPolyradiculitis |
| spellingShingle | Josef Finsterer Fulvio A. Scorza Carla A. Scorza Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients Clinics SARS-CoV-2 COVID-19 Neuro-COVID Complications Vaccination Polyradiculitis |
| title | Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients |
| title_full | Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients |
| title_fullStr | Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients |
| title_full_unstemmed | Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients |
| title_short | Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients |
| title_sort | post sars cov 2 vaccination guillain barre syndrome in 19 patients |
| topic | SARS-CoV-2 COVID-19 Neuro-COVID Complications Vaccination Polyradiculitis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100428&tlng=en |
| work_keys_str_mv | AT joseffinsterer postsarscov2vaccinationguillainbarresyndromein19patients AT fulvioascorza postsarscov2vaccinationguillainbarresyndromein19patients AT carlaascorza postsarscov2vaccinationguillainbarresyndromein19patients |